Skip to main content

Table 3 Serious Adverse Events (SOC term) occurring in ≥0.5% of patients per agent

From: Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

Exposure (Total, Mean pt.yrs) IFX GLM
1251, 3.2 675, 1.6
SOC N of Events N of Patients % of Patients Rate/100 Pt-Yrs N of Events N of Patients % of Patients Rate/100 Pt-Yrs
TOTAL 130 60 15.4% 10.5 57 34 8.1% 8.45
Blood and lymphatic system disorders 0 0 0 0 1 1 0.2% 0.15
Cardiac disorders 13 8 2.1% 1.05 3 3 0.7% 0.44
Eye disorders 2 2 0.5% 0.16 1 1 0.2% 0.15
Gastrointestinal disorders 17 12 3.1% 1.37 7 6 1.4% 1.04
General disorders and administration site conditions 13 11 2.8% 1.05 6 6 1.4% 0.89
Hepatobiliary disorders 7 6 1.5% 0.56 0 0 0 0
Infections and infestations 16 12 3.1% 1.29 15 10 2.4% 2.22
Injury, poisoning and procedural complications 6 6 1.5% 0.48 4 3 0.7% 0.59
Metabolism and nutrition disorders 1 1 0.3% 0.08 2 2 0.5% 0.3
Musculoskeletal and connective tissue disorders 7 5 1.3% 0.56 2 2 0.5% 0.3
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 6 6 1.5% 0.48 4 4 1.0% 0.59
Nervous system disorders 5 5 1.3% 0.40 2 2 0.5% 0.3
Psychiatric disorders 1 1 0.3% 0.08 2 2 0.5% 0.3
Renal and urinary disorders 4 3 0.8% 0.32 3 2 0.5% 0.44
Reproductive system and breast disorders 4 3 0.8% 0.32 1 1 0.2% 0.15